Standard Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History

Standard Family Office’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6	Closed	-$4K	–	350
2022 Q3	$4K	Hold	6	–	–	﹤0.01%	331
2022 Q2	$4K	Buy	+6	New	+$3.9K	0.04%	134
2022 Q1	–	Sell	-5	Closed	-$3K	–	210
2021 Q4	$3K	Buy	+5	New	+$3.07K	0.03%	172
2021 Q3	–	Sell	-5	Closed	-$3K	–	425
2021 Q2	$3K	Hold	5	–	–	﹤0.01%	320
2021 Q1	$2K	Hold	5	–	–	﹤0.01%	463
2020 Q4	$2K	Buy	+5	New	+$2.7K	﹤0.01%	477

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Standard Family Office's REGN Position: Q4 2022 in Review

Standard Family Office sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 6 shares — an estimated $4K sold.

Standard Family Office first reported a position in REGN in Q4 2020 and held it in 6 quarters. The position peaked at $4K in Q3 2022. 1,158 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

Standard Family Office reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Standard Family Office sold 6 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $4K.
Standard Family Office first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Standard Family Office's Regeneron Pharmaceuticals position peaked at $4K in Q3 2022.
1,158 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Standard Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.